CoAxia presents SENTIS clinical trial for ischemic stroke at 2010 Congress in Seoul CoAxia Inc.

Andrew M. Weiss, President and CEO commented, ‘CoAxia can be grateful for the participation of stroke teams from the US, Canada, Europe and Israel – for their assist in conducting this ground-breaking trial.’.. CoAxia presents SENTIS clinical trial for ischemic stroke at 2010 Congress in Seoul CoAxia Inc. Professor Shuaib, Director of Stroke Providers, University of Edmonton INFIRMARY, referred to the SENTIS trial results the following: whereas the NeuroFlo treatment didn’t attain statistical significance in its primary efficacy measure, it do achieve the trial’s major security endpoint and demonstrated many positive indications of both protection and advantage. The SENTIS trial included patients presenting with strokes up to 14 hours after symptom onset with baseline stroke severity NIHSS scores between 5 and 18.Immune function supportWell referred to as a powerful biological response modifier Glucans support the disease fighting capability nutritionally. Its therapeutic results are completed through Macrophage conversation enhancing the production, function and size of NK-Cells, B-Cells and T-Cells. These cells, as a matter of course, are essential to wage battle against bacteria, microbes, fungi and viruses. In addition, extensive study has verified that immune systems backed by quality Beta Glucans initiated improved phagocytosis and elevated apoptosis among tumor cells. Companies spend huge amount of money on so-called analysis and millions even more on advertisements to convince us to understand this vaccine or another. An excellent place to begin for accurate immune modulation Perhaps, instead of vaccine induced immune lethargy, has been Beta Glucans.